Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT04541173 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Due to slow accrual.

Conditions

Hepatocellular Carcinoma

Interventions

OTHER: Y-90 TARE
DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

Aiwu Ruth He, MD

Collaborators

[object Object]
[object Object]